loading page

“Evaluating Triplet Regimens for Advanced Biliary Tract Cancer: A Meta-analysis of Safety and Efficacy Profiles”
  • +4
  • Md. Al Hasibuzzaman,
  • Faiza Zakaria,
  • Anusha Ashkar,
  • Mirza Mehmood Ali Baig,
  • Taqia Fauzia,
  • Shayan Ali Irfan,
  • Muhammed Umer
Md. Al Hasibuzzaman
The First Affiliated Hospital of Ningbo University

Corresponding Author:[email protected]

Author Profile
Faiza Zakaria
Dow University of Health Sciences
Author Profile
Anusha Ashkar
Dow University of Health Sciences
Author Profile
Mirza Mehmood Ali Baig
Dow University of Health Sciences
Author Profile
Taqia Fauzia
Mohtarma Benazir Bhutto Shaheed Medical College
Author Profile
Shayan Ali Irfan
Dow University of Health Sciences
Author Profile
Muhammed Umer
Dow University of Health Sciences
Author Profile

Abstract

Objective: Biliary Tract Cancer (BTC) is a significant health concern with limited resectable cases. This meta-analysis assessed the safety of triplet regimens for advanced BTC, specifically gemcitabine, cisplatin, nab-paclitaxel, and gemcitabine, oxaliplatin, erlotinib, along with their associated adverse events. Method: Following PRISMA guidelines, we systematically reviewed PubMed/Medline, Google Scholar, and the Cochrane Library from inception to November 2022. Results: Our analysis of 5 studies favored Gem+Cisplatin+nab-Paclitaxel over GEMOX-T in terms of safety and adverse events. Qualitative analysis of 7 studies (491 patients) showed that Gem+Cisplatin+nab-Paclitaxel also outperformed in median overall survival, progression-free survival, and response rates. Conclusion: This study suggests that Gem+Cisplatin+nab-Paclitaxel is a safer and more effective treatment than GEMOX-T for advanced BTC. It exhibits superior outcomes in terms of survival and response rates. Further research should focus on optimizing treatment regimens to reduce adverse effects in advanced BTC patients.
27 Mar 2024Submitted to Cancer Reports
03 Apr 2024Submission Checks Completed
03 Apr 2024Assigned to Editor
03 Apr 2024Review(s) Completed, Editorial Evaluation Pending
08 Apr 2024Reviewer(s) Assigned
12 Jul 2024Editorial Decision: Revise Major